Patients who take GLP-1 receptor agonist medications before undergoing bariatric surgery achieve weight loss outcomes at the one-year mark that are similar to patients who have never used the drugs, according to a retrospective study published in JAMA Surgery. Researchers at the University of California San Francisco analyzed 383 primary bariatric surgeries and found that preoperative drug users lost 24% of their total body weight, compared with 25% for non-users, challenging assumptions about how medical and surgical obesity treatments interact.
Preoperative GLP-1 Use Shows No Impact on One-Year Weight Loss
The retrospective review, led by Jonathan Carter, MD, evaluated primary bariatric procedures performed at a single center between 2022 and 2024. Among the 383 total patients included in the analysis, 92 individuals had taken GLP-1 drugs prior to their operations, while 291 were naive to the medication class. Average postsurgical weight loss also showed no statistical difference, landing at 66 lb for users and 71 lb for non-users, according to the data.
Carter noted in an interview with MedPage Today that he was slightly surprised by the findings. Clinicians previously harbored concerns that preoperative exposure to medications that mimic the GLP-1 hormone might blunt subsequent surgical success, given that bariatric procedures inherently augment GLP-1 levels. However, the study demonstrated that patients who presumably lost weight on medications beforehand still achieved additional weight loss after surgery.
Pro Tip: Clinicians emphasize that obesity management should not be viewed as a competition between medicine and surgery, as patients frequently combine these therapies successfully over time.
Contrasting Findings and the Need for Sequencing Research
The UC San Francisco findings largely align with two recent retrospective studies that similarly identified no difference in 12-month postoperative weight loss between GLP-1 users and non-users. Conversely, a separate study reported that patients taking preoperative semaglutide lost less weight after surgery than naive patients at one year, posting a 21% loss compared to 26%.
Because the existing literature contains conflicting data, Carter emphasized the necessity of larger cohort studies and further research focused on optimal treatment sequencing. Anecdotal reports indicate that many patients add GLP-1 receptor agonists years after bariatric surgery to reach normal or near-normal body weights, highlighting an evolving clinical understanding of combination therapy.
Patient Demographics and Surgical Procedure Breakdown
The patient cohort studied by Carter and colleagues averaged 44 years of age, and 80% of the participants were female. Baseline body mass index for the group hovered around 44. The overwhelming majority of patients underwent sleeve gastrectomy, accounting for 83-88% of procedures, while 12-17% underwent gastric bypass.
Preoperative pharmaceutical regimens varied across the cohort. Semaglutide formulations were most common, representing 63% of drug usage across oral options like Rybelsus and injectables such as Ozempic and Wegovy. Other agents included dulaglutide, liraglutide, and tirzepatide, though only 4% of patients took tirzepatide, and most individuals were not prescribed the maximum dose.
Diabetes Control, Complications, and Postoperative Discontinuation
Baseline characteristics were generally balanced between the cohorts, with two notable exceptions: 51% of GLP-1 users had a diabetes diagnosis compared to 16% of non-users, and the drug group registered a higher baseline HbA1c of 6.5% versus 5.7%. Despite these differences, multivariate regression confirmed that preoperative drug use did not predict total weight loss.
Furthermore, operative times, hospital stays, 30-day emergency department visits, and complication rates remained comparable across both groups. Both populations also achieved excellent 12-month HbA1c control, averaging 5.4% for users and 5.3% for non-users. Only 15 patients resumed the medication postsurgery—five for diabetes management, eight for weight control, and two for unknown reasons—and they experienced 12-month weight loss comparable to the rest of the cohort at 22%.
Did You Know? Higher baseline BMI and male sex independently predicted greater weight loss in the study, whereas a diabetes diagnosis and undergoing a sleeve gastrectomy predicted less overall weight loss.
Frequently Asked Questions
Do GLP-1 drugs reduce the effectiveness of bariatric surgery?
According to research published in JAMA Surgery, patients taking GLP-1 medications prior to bariatric surgery achieve the same 12-month weight loss percentages as non-users.
Which surgical procedures were most common in the study?
The vast majority of patients in the UC San Francisco study underwent a sleeve gastrectomy, which comprised 83-88% of the procedures analyzed.
Can patients take GLP-1 medications after bariatric surgery?
What is your perspective on combining medications and bariatric surgery? Share your thoughts or questions in the comments below, and subscribe to our newsletter for the latest clinical updates.